Aerie Pharmaceuticals Inc

-0.56 (-4.81%)
Other Pre-Announcement

Aerie Pharmaceuticals Q2 Non-GAAP Loss Per Share $0.32

Published: 08/04/2022 20:26 GMT
Aerie Pharmaceuticals Inc (AERI) - Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update.
Q2 Non-GAAP Loss per Share $0.32.
Q2 Loss per Share $0.41.
Aerie Expects to Be Cash Flow Break Even During 2024.
Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for Remainder of 2022.
Q2 Glaucoma Franchise Net Revenues of $33.3 Million, Up 23%.
Q2 Earnings per Share View $-0.56, Revenue View $32.5 Million -- Refinitiv Ibes Data (analyst estimates).
Sees FY Total Glaucoma Franchise Net Product Revenues of $130 Million to $140 Million.